The stock's fall snapped a three-day winning streak.

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...

LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Regeneron Pharmaceuticals said it is collaborating with Truveta and its network of U.S. health systems to extend its DNA sequence-linked healthcare database. The company said Monday that it will ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.